The FDA approval of anti-CTLA-4 for the treatment of metastatic melanoma and of anti-PD-1 for metastatic melanoma and non-small cell lung cancer has engendered new-found awareness among oncologists of the potential antitumor activity of immune checkpoint modulation. This evidence concerns the gene PDCD1 and metastatic melanoma.